C
Caris Life Sciences, Inc. Common Stock (CAI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$21.00
-2.04 (-8.85%)
Market Cap: $6.61B
Last updated: Nov 17, 2026 at 11:04 AM ET
Caris Life Sciences, Inc. Common Stock (CAI) Valuation Multiples
Caris Life Sciences, Inc. Common Stock (CAI) trades at 5.7x sales and 9.3x book value. Its forward P/E is 31.6x.
Current Multiples
Its free cash flow yield is 0.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 31.6x |
| Price to sales | 5.7x |
| Price to book | 9.3x |
| Price to FCF | 206.2x |
|---|---|
| PEG | N/A |
| FCF yield | 0.5% |
As of Nov 17, 2026
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CAI
What is CAI's forward P/E ratio?
Caris Life Sciences, Inc. Common Stock has a forward P/E ratio of 31.6x.
Is CAI stock overvalued?
GNG's valuation label for CAI is Undervalued.
What is CAI's price to sales ratio?
Caris Life Sciences, Inc. Common Stock has a price to sales ratio of 5.7x.
CAI pages: Overview, Forecast, Financials, Valuation, Competitors